FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program

FDA will prepare safety profiles for several new molecular entities, using data from the first year of post-market experience, under a pilot program that is part of the agency's response to the Institute of Medicine's recommendations for improving drug safety in the United States